Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 6 art units • 13 examiners • 0 of 15 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
The portfolio for Genmab A/S contains 14 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 12 distinct examiners and 6 distinct art units. This distribution suggests a diverse array of pharmaceutical technologies under review, requiring the company to navigate multiple different examination styles and technical standards simultaneously. The 12 distinct examiners involved indicate that most matters are receiving individual attention from different officials.
The busiest examiner is SKELDING, ZACHARY S, who is handling 3 pending office actions. While this examiner has the highest individual load, the 12 distinct examiners show that the workload is spread across the USPTO. The 6 distinct art units further demonstrate the technical breadth of the company's current biotechnology applications. This level of dispersion across 6 art units suggests that the portfolio covers several distinct biological or chemical sub-fields, each with its own specific examination criteria.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (7%) |
| §112 only | 2 (13%) |
| Double-patenting only | 2 (13%) |
| Double-patenting + other | 7 (47%) |
| Multi-statute (no §101) | 2 (13%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 3 | 59.7% | +41.2% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| DARPOLOR, JOSEPHINE KEBBEH | 1 | 62.1% | +39.3% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | — |
| 17046199 | AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | SKELDING, ZACHARY S | 117d overdue |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | BELYAVSKYI, MICHAIL A | 7d |
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | PETERS, ALEC JON | 19d |
| 18526959 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | SZPERKA, MICHAEL EDWARD | — |
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | — |
| 18556240 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | SULLIVAN, DENNIS JOHN | — |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | — |
| 18025206 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | DARPOLOR, JOSEPHINE KEBBEH | — |
| Art Unit | Apps |
|---|---|
| 1642 | 4 |
| 1644 | 4 |
| 1641 | 3 |
| 1643 | 1 |
| 1672 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18526959 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | — | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18556240 | ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME | SULLIVAN, DENNIS JOHN | 1642 | §112DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18025206 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §103DP | Final Rejection | — | Pending | Mar 08, 2023 |
| 18025202 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | PETERS, ALEC JON | 1641 | DP | Final Rejection | 19d | Pending | Mar 08, 2023 |
| 18023808 | ANTIBODY THERAPY | SALVOZA, M FRANCO G | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | §102§112Other | Non-Final OA | — | Pending | Feb 14, 2023 |
| 18160386 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jan 27, 2023 |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | 7d | Pending | Dec 15, 2022 |
| 17714735 | MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS | GODDARD, LAURA B | 1642 | §112 | Non-Final OA | — | Pending | Apr 06, 2022 |
| 17046199 | AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT | ROONEY, NORA MAUREEN | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Oct 08, 2020 |
| 16891796 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 1646 | DPOther | Final Rejection | — | Pending | Jun 03, 2020 |
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | SKELDING, ZACHARY S | 1644 | §112DP | Non-Final OA | 117d overdue | Pending | Dec 04, 2019 |
| 16582428 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | — | Pending | Sep 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial